Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 save search
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
Published: 2023-06-28 (Crawled : 11:00) - globenewswire.com
CGTX | News | $2.0 0.0% 110K
|
|
| O: -10.0%
H: 2.67%
C: -3.11%
ct1812 disease alzheimer’s positive topline therapeutics results study phase 2
First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
Published: 2023-06-28 (Crawled : 11:00) - globenewswire.com
FWBI | $3.04 -2.56% -2.63% 37K
|
Manufacturing
|
| O: 1.9%
H: 0.0%
C: -3.73%
biopharma adrulipase trial phase 2
Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer
Published: 2023-06-27 (Crawled : 12:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M
|
Health Technology
|
| O: -0.14%
H: 0.74%
C: 0.09%
cancer women trial results phase 2
Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
Published: 2023-06-27 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: 3.1%
H: 0.94%
C: -3.21%
drug group pharmaceuticals program phase 2
Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine
Published: 2023-06-26 (Crawled : 12:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K
|
|
| O: 1.9%
H: 3.04%
C: -1.86%
au8 als publication treatment phase 2
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
Published: 2023-06-26 (Crawled : 11:00) - globenewswire.com
AVTX | $13.95 7.31% 6.81% 37K
|
Manufacturing
|
| O: -82.76%
H: 14.16%
C: -34.4%
avtx-002 topline trial phase 2
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
Published: 2023-06-25 (Crawled : 16:20) - globenewswire.com
MLTX | $42.45 -1.85% -1.88% 220K
|
| Email alert
Add to watchlist
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
nanobody positive results milestone phase 2
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
Published: 2023-06-24 (Crawled : 12:20) - globenewswire.com
ETNB | $8.59 -3.7% -3.84% 870K
|
Health Technology
| Email alert
Add to watchlist
positive trial results phase 2
Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®
Published: 2023-06-22 (Crawled : 13:00) - biospace.com/
EOLS | $11.48 -1.88% -1.92% 260K
|
Health Technology
|
| O: -0.12%
H: 0.37%
C: -2.08%
jeuveau study phase 2
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
Published: 2023-06-21 (Crawled : 14:00) - biospace.com/
DMAC | $2.5 3.31% 3.2% 7.4K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.91%
dm199 fda stroke trial therapeutics phase 2
Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease
Published: 2023-06-21 (Crawled : 12:00) - prnewswire.com
IKT | $1.64 3.8% 3.66% 62K
|
Health Technology
|
| O: 6.54%
H: 0.0%
C: -7.94%
disease ikt-148009 parkinson's medical trial therapeutics phase 2
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
Published: 2023-06-20 (Crawled : 12:00) - globenewswire.com
ICVX | $15.31 -0.65% 9.3M
|
|
| O: -3.73%
H: 9.27%
C: 5.39%
rsv trial phase 2
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
Published: 2023-06-20 (Crawled : 05:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -0.23%
H: 0.73%
C: 0.57%
study phase 2
Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program
Published: 2023-06-19 (Crawled : 00:00) - prnewswire.com
ACLX | $52.795 -3.02% -3.12% 300K
|
|
| O: -4.44%
H: 0.76%
C: -2.86%
program phase 2
Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial
Published: 2023-06-16 (Crawled : 12:20) - globenewswire.com
IXHL | $2.28 -1.29% 32K
|
Manufacturing
|
| O: -3.39%
H: 3.78%
C: 0.55%
ihl-42 trial phase 2
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.42%
H: 0.0%
C: 0.0%
IPHA | $2.47 4.22% 4.05% 690
|
Health Technology
|
| O: 1.84%
H: 6.63%
C: 4.82%
pharma results study phase 2
Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program
Published: 2023-06-15 (Crawled : 12:20) - globenewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 0.97%
H: 0.64%
C: 0.64%
FBIO | $1.785 -1.38% -1.4% 120K
|
Health Technology
|
| O: 2.42%
H: 10.78%
C: 7.94%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 1.68%
H: 1.0%
C: 0.84%
cancer grant program trial phase 2
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
Published: 2023-06-15 (Crawled : 11:00) - globenewswire.com
AVIR | $3.705 -0.67% -0.67% 200K
|
Health Technology
|
| O: -0.24%
H: 2.94%
C: 1.72%
hepatitis bemnifosbuvir treatment pharmaceuticals study phase 2
Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
Published: 2023-06-13 (Crawled : 12:00) - globenewswire.com
RXRX | $7.94 3.12% 3.02% 7.1M
|
Professional, Scientific, and T...
|
| O: -1.02%
H: 4.62%
C: 1.95%
treatment trial phase 2
First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis
Published: 2023-06-13 (Crawled : 11:00) - globenewswire.com
FWBI | $3.04 -2.56% -2.63% 37K
|
Manufacturing
|
| O: 150.48%
H: 4.89%
C: -46.85%
biopharma fibrosis adrulipase trial phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.